INS and type 1 diabetes mellitus: A trial employing intranasal insulin administration to halt autoimmune β-cell destruction in new-onset T1D patients with slowly evolving disease did not result in significant β-cell preservation, despite evidence that insulin-specific immune tolerance was successfully induced (9).